2025-10-04 - Analysis Report
Okay, here's an analysis of UnitedHealth Group (UNH) based on the data you provided, formatted for readability with English summaries and concise explanations.

## UnitedHealth Group Inc. (UNH) Analysis

**Company Overview:** UnitedHealth Group is a diversified healthcare company providing a wide range of products and services.

### 1. Performance vs. S&P 500 (VOO)

*   **UNH Cumulative Return:** -15.89%
*   **VOO Cumulative Return:** 98.51%
*   **Absolute Divergence:** -115.9
*   **Relative Divergence:** 8.9 (meaning UNH's divergence is in the 8.9th percentile of its historical range).

**Summary:** UNH has significantly underperformed the S&P 500. The large negative divergence suggests substantial underperformance relative to the broader market. The Relative Divergence indicates that this underperformance is near the lower end of its historical range compared to the S\&P 500.

#### Alpha/Beta Analysis

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2015-2017  | 58.0%   | 66.4%   | 30.0%   | 0.1   | 199.7  |
| 2016-2018  | 41.0%   | 70.4%   | 26.0%   | 0.1   | 225.6  |
| 2017-2019  | 36.0%   | 73.8%   | 14.0%   | 0.2   | 266.2  |
| 2018-2020  | -43.0%  | 81.2%   | -67.0%  | 0.5   | 317.6  |
| 2019-2021  | 16.0%   | 81.2%   | -30.0%  | 1.5   | 454.8  |
| 2020-2022  | -1.0%   | 81.2%   | 0.0%    | 1.5   | 480.2  |
| 2021-2023  | 24.0%   | 80.8%   | 23.0%   | 0.4   | 476.8  |
| 2022-2024  | -27.0%  | 78.8%   | -47.0%  | 0.3   | 458.1  |
| 2023-2025  | -58.0%  | 78.8%   | -121.0% | 1.3   | 326.2  |

**Analysis:**

*   **CAGR:**  Shows fluctuating growth rates over different periods, with recent periods showing negative CAGR.
*   **MDD:** High Maximum Drawdown values indicate significant potential losses from peak to trough.
*   **Alpha:**  Generally positive in earlier periods, but significantly negative in recent years, implying underperformance relative to its benchmark.
*   **Beta:**  Low Beta values (below 1) in earlier periods suggest lower volatility than the market.  Increased Beta values in recent years indicate UNH's price is now more sensitive to market movements.
*   **Cap(B):**  Market capitalization increased significantly over the period, but has decreased more recently.

### 2. Recent Stock Price Movement

*   **Current Price:** 360.20
*   **Last Market Data:** `{'price': 360.2, 'previousClose': 353.72, 'change': 1.83}`
*   **5-day Moving Average:** 350.73
*   **20-day Moving Average:** 345.39
*   **60-day Moving Average:** 304.36

**Summary:**  The stock price is above all three moving averages, indicating a short-term upward trend.  The recent price increase (change of 1.83) and current price relative to the previous close confirm this short-term positive momentum.

### 3. Technical Indicators & Expected Return

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 60.40 (Approaching overbought territory, but not yet there)
*   **PPO:** -0.26 (Slightly negative, suggesting a potential buying opportunity, but needs further confirmation)
*   **Hybrid Signal:** "cash\_0% Buy 100% of cash (1 shares - Very Safe - MRI:0.90)" (Aggressive Buy signal based on the algorithm).
*   **Delta\_Previous\_Relative\_Divergence:** -0.3 (Short-term decline in relative performance)
*   **Expected Return:** -139.6% (Significant negative expected return compared to the S&P 500 over the long term)

**Summary:** While the MRI indicates a high investment recommendation, and the hybrid signal suggests a "buy," the significantly negative expected return and recent decline in relative divergence are concerning. The RSI suggests the stock is not yet overbought, and the PPO is slightly negative.

### 4. Recent News & Analyst Opinions

*   **Recent News:**  Positive headlines include "UnitedHealth Group (UNH) Laps the Stock Market" and "Bernstein Reaffirms Buy Rating." This indicates positive sentiment surrounding the stock despite recent underperformance.
*   **Analyst Consensus:**
    *   Mean Rating: 1.96 (~Buy)
    *   Target Price: Average $340.50 (significantly below current price).
    *   Recent Rating Changes:  Not available in provided data.

**Summary:** Analyst sentiment is generally positive, but the average target price is below the current stock price, suggesting limited upside potential or possible overvaluation. The recent news headlines, however, indicate some positive catalysts.

### 5. & 6. Recent Earnings & Financial Information

**Earnings:**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2025-08-11 | 3.76 | 111.62 B$   |
| 2025-05-07 | 6.9  | 109.58 B$   |
| 2024-11-04 | 6.56 | 100.82 B$   |
| 2024-08-09 | 4.58 | 98.86 B$   |
| 2025-08-11 | 4.58 | 98.86 B$   |

**Revenue and Profitability:**

| Quarter    | Revenue       | Profit Margin |
|------------|---------------|---------------|
| 2025-06-30 | $111.62B     | 17.93%        |
| 2025-03-31 | $109.58B     | 21.70%        |
| 2024-12-31 | $100.81B     | 21.14%        |
| 2024-09-30 | $100.82B     | 22.84%        |
| 2024-06-30 | $98.86B     | 22.31%        |

**Capital and Profitability:**

| Quarter    | Equity        | ROE   |
|------------|---------------|-------|
| 2025-06-30 | $94.72B     | 3.60% |
| 2025-03-31 | $95.04B     | 6.62% |
| 2024-12-31 | $92.66B     | 5.98% |
| 2024-09-30 | $94.53B     | 6.41% |
| 2024-06-30 | $89.36B     | 4.72% |

**Analysis:**

*   **Earnings:** Revenue shows a general upward trend. EPS is variable.
*   **Revenue & Profitability:**  Revenue is growing, but profit margins have fluctuated and decreased in the most recent quarter.
*   **Capital & Profitability:** Equity is relatively stable. ROE has also fluctuated, decreasing significantly in the most recent quarter.

### 7. Overall Summary

UnitedHealth Group (UNH) shows a mixed picture.  While recent price movement is positive and analyst sentiment is generally bullish, the stock has significantly underperformed the S&P 500, and the long-term expected return is alarmingly negative.  Recent news headlines are positive, and the MRI is high, but declining profit margins, ROE and negative alpha are causes for concern. The average analyst target price is below the current price, indicating limited upside based on their expectations.
